 Shanlee Davis
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 14 | 2025 | 56 | 5.710 |
Why?
| | Turner Syndrome | 9 | 2024 | 51 | 4.520 |
Why?
| | Sex Chromosome Disorders | 3 | 2025 | 20 | 2.450 |
Why?
| | XYY Karyotype | 4 | 2025 | 21 | 1.920 |
Why?
| | Trisomy | 3 | 2025 | 77 | 1.890 |
Why?
| | Sex Chromosome Aberrations | 8 | 2025 | 62 | 1.700 |
Why?
| | Testosterone | 5 | 2022 | 372 | 1.410 |
Why?
| | Chromosomes, Human, X | 5 | 2025 | 69 | 1.400 |
Why?
| | Mosaicism | 4 | 2024 | 69 | 1.360 |
Why?
| | Oxandrolone | 3 | 2018 | 8 | 1.280 |
Why?
| | Sex Chromosome Disorders of Sex Development | 3 | 2025 | 15 | 1.130 |
Why?
| | Cardiovascular Diseases | 5 | 2025 | 2008 | 1.010 |
Why?
| | Puberty | 4 | 2024 | 143 | 0.870 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 51 | 0.830 |
Why?
| | Neurodevelopmental Disorders | 1 | 2025 | 154 | 0.780 |
Why?
| | Registries | 4 | 2024 | 1903 | 0.760 |
Why?
| | Testis | 3 | 2018 | 144 | 0.730 |
Why?
| | Child | 27 | 2025 | 20962 | 0.730 |
Why?
| | Monosomy | 1 | 2021 | 11 | 0.720 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 38 | 0.700 |
Why?
| | Ovarian Reserve | 1 | 2020 | 14 | 0.680 |
Why?
| | Inhibins | 1 | 2020 | 45 | 0.680 |
Why?
| | Mental Disorders | 3 | 2025 | 1035 | 0.670 |
Why?
| | Dyslipidemias | 1 | 2022 | 177 | 0.670 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 111 | 0.670 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 340 | 0.670 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 34 | 0.670 |
Why?
| | Androgens | 2 | 2018 | 177 | 0.660 |
Why?
| | Body Composition | 3 | 2020 | 649 | 0.620 |
Why?
| | Case-Control Studies | 6 | 2025 | 3384 | 0.610 |
Why?
| | Electronic Health Records | 3 | 2025 | 979 | 0.570 |
Why?
| | Aneuploidy | 5 | 2024 | 92 | 0.560 |
Why?
| | Phenotype | 6 | 2024 | 3062 | 0.530 |
Why?
| | Adolescent | 20 | 2025 | 20451 | 0.520 |
Why?
| | Prevalence | 6 | 2025 | 2564 | 0.520 |
Why?
| | Body Height | 1 | 2017 | 192 | 0.500 |
Why?
| | Adipose Tissue | 1 | 2019 | 594 | 0.490 |
Why?
| | Infertility, Male | 1 | 2015 | 61 | 0.480 |
Why?
| | Child Development | 1 | 2019 | 459 | 0.470 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.460 |
Why?
| | Sex Chromosomes | 3 | 2024 | 50 | 0.450 |
Why?
| | Male | 29 | 2025 | 63759 | 0.440 |
Why?
| | Humans | 41 | 2025 | 129847 | 0.440 |
Why?
| | Female | 26 | 2025 | 68829 | 0.420 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 37 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1242 | 0.410 |
Why?
| | Child, Preschool | 14 | 2025 | 10522 | 0.400 |
Why?
| | Veterans | 1 | 2024 | 1383 | 0.390 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 197 | 0.380 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1003 | 0.370 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1644 | 0.370 |
Why?
| | Obesity | 2 | 2022 | 2885 | 0.350 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5085 | 0.340 |
Why?
| | Estradiol | 2 | 2023 | 494 | 0.300 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 20 | 0.250 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 397 | 0.250 |
Why?
| | Epilepsy | 1 | 2010 | 322 | 0.250 |
Why?
| | Morbidity | 2 | 2024 | 302 | 0.240 |
Why?
| | Infant, Newborn | 4 | 2024 | 5772 | 0.230 |
Why?
| | Karyotype | 2 | 2023 | 17 | 0.230 |
Why?
| | Blood Glucose | 1 | 2014 | 2103 | 0.230 |
Why?
| | Double-Blind Method | 3 | 2018 | 1877 | 0.230 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 69 | 0.220 |
Why?
| | Young Adult | 8 | 2024 | 12467 | 0.220 |
Why?
| | Y Chromosome | 1 | 2023 | 6 | 0.220 |
Why?
| | Infant | 6 | 2024 | 9018 | 0.220 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4896 | 0.200 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 6 | 0.190 |
Why?
| | Oxadiazoles | 1 | 2022 | 33 | 0.190 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 27 | 0.190 |
Why?
| | Quality of Life | 2 | 2024 | 2695 | 0.190 |
Why?
| | Comorbidity | 2 | 2025 | 1551 | 0.190 |
Why?
| | Phosphocreatine | 1 | 2021 | 43 | 0.190 |
Why?
| | Body Mass Index | 2 | 2020 | 2274 | 0.180 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 81 | 0.180 |
Why?
| | Transgender Persons | 1 | 2024 | 172 | 0.180 |
Why?
| | Adult | 10 | 2024 | 35634 | 0.180 |
Why?
| | Genitalia | 1 | 2021 | 30 | 0.180 |
Why?
| | Gonadotropins | 1 | 2020 | 38 | 0.170 |
Why?
| | Prognosis | 2 | 2019 | 3773 | 0.160 |
Why?
| | Developmental Disabilities | 2 | 2016 | 254 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 307 | 0.160 |
Why?
| | Waist Circumference | 1 | 2020 | 138 | 0.160 |
Why?
| | Magnetoencephalography | 1 | 2020 | 128 | 0.160 |
Why?
| | Hypogonadism | 1 | 2020 | 84 | 0.160 |
Why?
| | Genetic Association Studies | 1 | 2021 | 357 | 0.160 |
Why?
| | Inservice Training | 1 | 2020 | 111 | 0.160 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 279 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 541 | 0.160 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.160 |
Why?
| | Failure to Thrive | 1 | 2019 | 29 | 0.150 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 482 | 0.150 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.150 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 180 | 0.150 |
Why?
| | Face | 1 | 2020 | 165 | 0.150 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 26 | 0.150 |
Why?
| | Growth Disorders | 1 | 2019 | 81 | 0.150 |
Why?
| | Mentors | 1 | 2020 | 177 | 0.150 |
Why?
| | Triglycerides | 1 | 2020 | 528 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 279 | 0.140 |
Why?
| | Mentoring | 1 | 2020 | 132 | 0.140 |
Why?
| | Overweight | 1 | 2022 | 531 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 763 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 318 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 796 | 0.130 |
Why?
| | Cohort Studies | 3 | 2020 | 5444 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 530 | 0.130 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 23 | 0.130 |
Why?
| | Speech Disorders | 1 | 2016 | 34 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 900 | 0.130 |
Why?
| | Risk | 1 | 2019 | 860 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 45 | 0.130 |
Why?
| | Algorithms | 1 | 2023 | 1617 | 0.130 |
Why?
| | Language Development Disorders | 1 | 2016 | 44 | 0.130 |
Why?
| | Genetic Counseling | 1 | 2016 | 70 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1645 | 0.120 |
Why?
| | Research | 1 | 2019 | 420 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 947 | 0.120 |
Why?
| | Mitochondria | 1 | 2021 | 875 | 0.120 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 136 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 144 | 0.110 |
Why?
| | Muscle Strength | 1 | 2017 | 304 | 0.110 |
Why?
| | Sex Factors | 1 | 2019 | 1973 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 1920 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 636 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2739 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2021 | 1168 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2271 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2724 | 0.100 |
Why?
| | Hospitalization | 2 | 2024 | 2079 | 0.090 |
Why?
| | Autism Spectrum Disorder | 1 | 2017 | 386 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 427 | 0.090 |
Why?
| | United States | 2 | 2025 | 13913 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2022 | 10241 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 3971 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1686 | 0.080 |
Why?
| | Cognition | 1 | 2017 | 1125 | 0.080 |
Why?
| | Neoplasms | 1 | 2023 | 2454 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2677 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1112 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1221 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 175 | 0.070 |
Why?
| | Insulin | 1 | 2016 | 2330 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2444 | 0.060 |
Why?
| | Syndrome | 2 | 2020 | 338 | 0.060 |
Why?
| | Sexual Development | 1 | 2023 | 18 | 0.050 |
Why?
| | Europe | 1 | 2024 | 363 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 99 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1514 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 204 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 59 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 11 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 133 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 196 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 787 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 72 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2023 | 14553 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 386 | 0.040 |
Why?
| | Suicidal Ideation | 1 | 2024 | 493 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 422 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1465 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 227 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 250 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 206 | 0.040 |
Why?
| | Health Status | 1 | 2023 | 758 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3630 | 0.040 |
Why?
| | Universities | 1 | 2020 | 409 | 0.040 |
Why?
| | Social Media | 1 | 2020 | 141 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2016 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1434 | 0.030 |
Why?
| | Suicide | 1 | 2024 | 616 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 285 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2646 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 302 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 691 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 759 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 587 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 153 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 414 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 395 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 517 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1016 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1500 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 875 | 0.020 |
Why?
| | Parents | 1 | 2019 | 1319 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6423 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 976 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1323 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5437 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 31177 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|